CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: November 18, 2013
Result type: Reports
Project Number: SR0361-000
Product Line: Reimbursement Review

Generic Name: Aflibercept

Brand Name: Eylea

Manufacturer: Bayer Canada Inc.

Therapeutic Area: Macular degeneration, age-related

Indications: Macular degeneration, age-related

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 20, 2014

Recommendation Type: List with criteria/condition